Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventionalPhase 3

A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula

NCT ID: NCT06807437Sponsor: SWOG Cancer Research NetworkLast updated: 2026-03-31

Summary

This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of somatostatin analog similar to somatostatin (a hormone made by the body), and is used to treat certain types of gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome. It may help stop the body from making extra amounts of certain hormones, including growth hormone, insulin, glucagon, and hormones that affect digestion. It may also help keep certain types of tumor cells from growing. Patients with pancreatic cancer or pancreatic lesions may undergo surgery to remove parts of the pancreas, also called a distal pancreatectomy. Patients may experience complications after surgery, including pancreatic fistulas. A pancreatic fistula occurs when there is a small leak from the pancreas, causing fluids to collect. This can often lead to infection and other problems. Giving lanreotide before undergoing distal pancreatectomy may be more effective than surgery alone in preventing the development of a pancreatic fistula in patients with pancreatic cancer or a pancreatic lesion that could become cancerous.

Detailed description

PRIMARY OBJECTIVE: I. To compare the incidence of postoperative pancreatic fistula (POPF) occurring within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo prior to undergoing distal pancreatectomy for biopsy-proven or suspected neoplasm. SECONDARY OBJECTIVES: I. To compare the incidence of International Study Group of Pancreatic Surgery (ISGPS)-defined biochemical leak occurring within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo in the subset of participants with a drain placed. II. To compare the number of postoperative days in the hospital within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo. III. To compare change from baseline in cancer-specific quality of life at 14 and 60 days after surgery, as measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core 30-(C30), in participants randomized to receive preoperative lanreotide versus placebo. ADDITIONAL OBJECTIVES: I. To compare change from baseline in pancreatic cancer-specific quality of life and overall health-related quality of life at 14 and 60 days after surgery, as measured by the EORTC QLQ- Pancreatic Cancer 26 (PAN26) and European Quality of Life Five Dimension Five Level (EQ-5D-5L), in participants randomized to receive preoperative lanreotide versus placebo. II. To compare the proportions of participants with common postoperative sequelae associated with POPF, including ISGPS delayed gastric emptying and ISGPS post pancreatectomy hemorrhage (grades B/C) occurring within 60 days after surgery, in participants randomized to receive preoperative lanreotide versus placebo. III. To compare time from surgery to initiation of adjuvant chemotherapy among participants with pancreatic ductal adenocarcinoma and planned adjuvant chemotherapy randomized to receive preoperative lanreotide versus placebo. BANKING OBJECTIVE: I. To bank blood, pancreas fluid, and tissue specimens for future correlative studies. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive lanreotide subcutaneously (SC) over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and on post-operative days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3. ARM II: Patients receive saline placebo SC over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and post-operatively on days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3. After completion of study treatment, patients are followed up at 4, 8 and 12 months after surgery.

Arms & interventions

  • ProcedureBiospecimen Collection

    Undergo blood sample and pancreas fluid collection

  • ProcedureDistal Pancreatectomy

    Undergo distal pancreatectomy

  • DrugLanreotide

    Given SC

  • OtherQuestionnaire Administration

    Ancillary studies

  • OtherSaline

    Given SC

Outcome measures

Primary

  • Incidence of postoperative pancreatic fistula (POPF)

    POPF will be assessed using the 2016 International Study Group for Pancreas Surgery (ISGPS). Incidence rates of POPF in each treatment arm will be described, and treatment arm differences assessed via logistic regression model with adjustment for stratification factor.

    Time frame: Up to 60 days after distal pancreatectomy

Secondary

  • Incidence of biochemical leak (BL)

    Time frame: Up to 60 days after distal pancreatectomy

  • Number of post-operation hospital days

    Time frame: From the time of surgery up to 60 days after distal pancreatectomy

  • Change in overall quality of life (QOL)

    Time frame: At baseline and at 14 and 60 days after surgery

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: * Participants must have histologically or radiographically confirmed diagnosis of pancreatic cancer or a pancreatic lesion with malignant potential * Participants must have an elective distal pancreatectomy planned to occur within 60 days after registration/randomization date * Participants must not have a known history of a prior diagnosis of malabsorption syndrome * Participants must not have been treated with any somatostatin analogue within 180 days prior to registration/randomization * Participants must not have been treated with radiation therapy for their pancreas malignancy at any time prior to registration/randomization * Participants must not have been treated with peptide receptor radionuclide therapy (PRRT) at any time prior to registration/randomization * Participants must be ≥ 18 years old * Participants must have a complete documented medical history and physical exam within 28 days prior to registration/randomization * Participants must have a creatinine ≤ the institutional upper limit of normal (IULN) OR a measured OR calculated creatinine clearance ≥ 50 mL/min using the following Cockcroft -Gault formula within 60 days prior to registration/randomization * Participants must complete a pre-registration screening to identify any of the medications below, allowing the study team and treating physician to develop a monitoring plan as needed. Participants taking medications with known interactions with lanreotide may remain eligible if appropriate monitoring and management are in place. These medications include: * Diabetes medications (insulin or oral hypoglycemics): Blood sugar will be monitored, and medication dose adjustments made as needed * Cyclosporine: Dosage adjustments may be required to maintain therapeutic levels * Bromocriptine: Dose adjustments may be considered to account for absorption changes * Heart medications (e.g., beta blockers): Heart rate will be monitored, and medication doses adjusted if necessary * CYP3A4-metabolized medications: Dose adjustments may be considered to avoid increased exposure * In the opinion of the treating surgeon, based on preoperative data, the participant must not require a modified Appleby-type procedure (distal pancreatectomy with celiac axis resection) or multivisceral resection (e.g., stomach, colon, etc.) at the time of distal pancreatectomy * NOTE: planned removal of the gallbladder or spleen at the time of distal pancreatectomy is not considered multivisceral resection and is permissible * In the opinion of the treating surgeon, based on preoperative data, the participant must not require a tumor enucleation * Participants must not have moderate to severe hepatic impairment as defined by liver enzyme elevation more than 5 times the institutional upper limit of normal (either aspartate aminotransferase \[AST\] \> 190 U/L or alanine aminotransferase \[ALT\] \> 320 U/L) within 60 days prior to registration/randomization. Transient elevation at the time of screening that resolves prior to study enrollment is acceptable * Participants must not be pregnant or nursing (nursing includes breast milk fed to an infant by any means, including from the breast, milk expressed by hand, or pumped) * Individuals who are of reproductive potential must have agreed to use an effective contraceptive method during the whole period of the study and for three months after the study drug administration, with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen * Participants must be offered the opportunity to participate in specimen banking * Participants who can complete EORTC QLQ-C30, EORTC QLQ-PAN26, and EQ-5D-5L forms in English or Spanish, must be offered the opportunity to participate in the quality-of-life study * NOTE: As a part of the OPEN registration process, the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system. * Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines * For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations

Study locations (118)

University of Alabama at Birmingham Cancer Center

Birmingham, Alabama, 35233

Suspended

Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis

Daphne, Alabama, 36526

Suspended

Thomas Hospital

Fairhope, Alabama, 36532

Suspended

Mobile Infirmary Medical Center

Mobile, Alabama, 36607

Suspended

Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland

Saraland, Alabama, 36571

Suspended

Banner MD Anderson Cancer Center

Gilbert, Arizona, 85234

Suspended

City of Hope Comprehensive Cancer Center

Duarte, California, 91010

Suspended

UC San Diego Moores Cancer Center

La Jolla, California, 92093

Recruiting
Site Public Contact · Contact
Andrew M. Lowy · Principal Investigator

Veterans Affairs Loma Linda Healthcare System

Loma Linda, California, 92357

Suspended

USC / Norris Comprehensive Cancer Center

Los Angeles, California, 90033

Suspended

UC San Diego Medical Center - Hillcrest

San Diego, California, 92103

Suspended

Helen F Graham Cancer Center

Newark, Delaware, 19713

Suspended

Medical Oncology Hematology Consultants PA

Newark, Delaware, 19713

Suspended

Christiana Care Health System-Christiana Hospital

Newark, Delaware, 19718

Suspended

Christiana Care Health System-Wilmington Hospital

Wilmington, Delaware, 19801

Suspended

Moffitt Cancer Center at SouthShore

Ruskin, Florida, 33570

Suspended

Moffitt Cancer Center-International Plaza

Tampa, Florida, 33607

Suspended

Moffitt Cancer Center - McKinley Campus

Tampa, Florida, 33612

Recruiting
Site Public Contact · Contact
Andrew J. Sinnamon · Principal Investigator

Moffitt Cancer Center

Tampa, Florida, 33612

Suspended

Moffitt Cancer Center at Wesley Chapel

Wesley Chapel, Florida, 33544

Suspended

Grady Health System

Atlanta, Georgia, 30303

Suspended

Emory University Hospital Midtown

Atlanta, Georgia, 30308

Suspended

Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia, 30322

Suspended

Emory Saint Joseph's Hospital

Atlanta, Georgia, 30342

Suspended

Emory Johns Creek Hospital

Johns Creek, Georgia, 30097

Suspended

Northwestern University

Chicago, Illinois, 60611

Recruiting
Site Public Contact · Contact
Akhil Chawla · Principal Investigator

University of Illinois

Chicago, Illinois, 60612

Recruiting
Site Public Contact · Contact
Aslam Ejaz · Principal Investigator

Northwestern Medicine Cancer Center Delnor

Geneva, Illinois, 60134

Suspended

Northwestern Medicine Oak Brook

Oak Brook, Illinois, 60523

Suspended

Northwestern Medicine Orland Park

Orland Park, Illinois, 60462

Suspended

Northwestern Medicine Cancer Center Warrenville

Warrenville, Illinois, 60555

Suspended

Indiana University/Melvin and Bren Simon Cancer Center

Indianapolis, Indiana, 46202

Suspended

University of Kentucky/Markey Cancer Center

Lexington, Kentucky, 40536

Recruiting
Site Public Contact · Contact
Michael J. Cavnar · Principal Investigator

University Medical Center New Orleans

New Orleans, Louisiana, 70112

Suspended

Christiana Care - Union Hospital

Elkton, Maryland, 21921

Suspended

University of Michigan Rogel Cancer Center

Ann Arbor, Michigan, 48109

Suspended

Bronson Battle Creek

Battle Creek, Michigan, 49017

Suspended

Corewell Health Grand Rapids Hospitals - Butterworth Hospital

Grand Rapids, Michigan, 49503

Suspended

Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital

Grand Rapids, Michigan, 49503

Suspended

Trinity Health Grand Rapids Hospital

Grand Rapids, Michigan, 49503

Suspended

Trinity Health Muskegon Hospital

Muskegon, Michigan, 49444

Suspended

Corewell Health Lakeland Hospitals - Niles Hospital

Niles, Michigan, 49120

Suspended

Cancer and Hematology Centers of Western Michigan - Norton Shores

Norton Shores, Michigan, 49444

Suspended

Corewell Health Reed City Hospital

Reed City, Michigan, 49677

Suspended

Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center

Saint Joseph, Michigan, 49085

Suspended

Corewell Health Lakeland Hospitals - Saint Joseph Hospital

Saint Joseph, Michigan, 49085

Suspended

University of Michigan Health - West

Wyoming, Michigan, 49519

Suspended

Riverwood Healthcare Center

Aitkin, Minnesota, 56431

Suspended

Essentia Health - Baxter Clinic

Baxter, Minnesota, 56425

Suspended

Essentia Health Saint Joseph's Medical Center

Brainerd, Minnesota, 56401

Suspended

Essentia Health - Saint Joseph's Crosslake Clinic

Crosslake, Minnesota, 56442

Suspended

Essentia Health - Deer River Clinic

Deer River, Minnesota, 56636

Suspended

Essentia Health Saint Mary's - Detroit Lakes Clinic

Detroit Lakes, Minnesota, 56501

Suspended

Essentia Health Cancer Center

Duluth, Minnesota, 55805

Suspended

Essentia Health Saint Mary's Medical Center

Duluth, Minnesota, 55805

Suspended

Miller-Dwan Hospital

Duluth, Minnesota, 55805

Suspended

Essentia Health - Ely Clinic

Ely, Minnesota, 55731

Suspended

Essentia Health - Fosston

Fosston, Minnesota, 56542

Suspended

Essentia Health Hibbing Clinic

Hibbing, Minnesota, 55746

Suspended

Essentia Health - International Falls Clinic

International Falls, Minnesota, 56649

Suspended

Essentia Health - Moose Lake Clinic

Moose Lake, Minnesota, 55767

Suspended

Essentia Health - Park Rapids

Park Rapids, Minnesota, 56470

Suspended

Essentia Health - Saint Joseph's Pequot Lakes Clinic

Pequot Lakes, Minnesota, 56472

Suspended

Essentia Health - Saint Joseph's Pine River Clinic

Pine River, Minnesota, 56474

Suspended

Essentia Health Sandstone

Sandstone, Minnesota, 55072

Suspended

Essentia Health - Saint Joseph's Staples Clinic

Staples, Minnesota, 56479

Suspended

Essentia Health Virginia Clinic

Virginia, Minnesota, 55792

Suspended

Parkland Health Center - Farmington

Farmington, Missouri, 63640

Recruiting
Site Public Contact · Contact
Bryan A. Faller · Principal Investigator

Sainte Genevieve County Memorial Hospital

Sainte Genevieve, Missouri, 63670

Recruiting
Site Public Contact · Contact
Bryan A. Faller · Principal Investigator

Missouri Baptist Medical Center

St Louis, Missouri, 63131

Recruiting
Site Public Contact · Contact
Bryan A. Faller · Principal Investigator

Missouri Baptist Sullivan Hospital

Sullivan, Missouri, 63080

Recruiting
Site Public Contact · Contact
Bryan A. Faller · Principal Investigator

BJC Outpatient Center at Sunset Hills

Sunset Hills, Missouri, 63127

Recruiting
Site Public Contact · Contact
Bryan A. Faller · Principal Investigator

University of Nebraska Medical Center

Omaha, Nebraska, 68198

Suspended

Renown Regional Medical Center

Reno, Nevada, 89502

Suspended

Saint Barnabas Medical Center

Livingston, New Jersey, 07039

Suspended

Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903

Suspended

University of New Mexico Cancer Center

Albuquerque, New Mexico, 87106

Suspended

University of Rochester

Rochester, New York, 14642

Suspended

State University of New York Upstate Medical University

Syracuse, New York, 13210

Suspended

Carolinas Medical Center/Levine Cancer Institute

Charlotte, North Carolina, 28203

Suspended

Atrium Health Cabarrus/LCI-Concord

Concord, North Carolina, 28025

Suspended

Essentia Health Cancer Center-South University Clinic

Fargo, North Dakota, 58103

Suspended

Sanford Broadway Medical Center

Fargo, North Dakota, 58122

Suspended

Sanford Roger Maris Cancer Center

Fargo, North Dakota, 58122

Suspended

Essentia Health - Jamestown Clinic

Jamestown, North Dakota, 58401

Suspended

University of Cincinnati Cancer Center-UC Medical Center

Cincinnati, Ohio, 45219

Suspended

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210

Suspended

University of Cincinnati Cancer Center-West Chester

West Chester, Ohio, 45069

Suspended

Saint Luke's Cancer Center - Allentown

Allentown, Pennsylvania, 18104

Recruiting
Site Public Contact · Contact
Darius C. Desai · Principal Investigator

Saint Luke's University Hospital-Bethlehem Campus

Bethlehem, Pennsylvania, 18015

Recruiting
Site Public Contact · Contact
Darius C. Desai · Principal Investigator

Christiana Care Health System-Concord Health Center

Chadds Ford, Pennsylvania, 19317

Suspended

Saint Luke's Hospital-Anderson Campus

Easton, Pennsylvania, 18045

Recruiting
Site Public Contact · Contact
Darius C. Desai · Principal Investigator

Saint Luke's Hospital - Upper Bucks Campus

Quakertown, Pennsylvania, 18951

Recruiting
Site Public Contact · Contact
Darius C. Desai · Principal Investigator

Saint Luke's Hospital - Monroe Campus

Stroudsburg, Pennsylvania, 18360

Recruiting
Site Public Contact · Contact
Darius C. Desai · Principal Investigator

Geisinger Wyoming Valley/Henry Cancer Center

Wilkes-Barre, Pennsylvania, 18711

Suspended

Sanford Cancer Center Oncology Clinic

Sioux Falls, South Dakota, 57104

Suspended

Sanford USD Medical Center - Sioux Falls

Sioux Falls, South Dakota, 57117-5134

Suspended

University of Tennessee - Knoxville

Knoxville, Tennessee, 37920

Suspended

Baptist Memorial Hospital and Cancer Center-Memphis

Memphis, Tennessee, 38120

Suspended

University of Vermont Medical Center

Burlington, Vermont, 05401

Suspended

University of Vermont and State Agricultural College

Burlington, Vermont, 05405

Suspended

VCU Massey Cancer Center at Stony Point

Richmond, Virginia, 23235

Recruiting
Site Public Contact · Contact
Leopoldo J. Fernandez · Principal Investigator

VCU Massey Comprehensive Cancer Center

Richmond, Virginia, 23298

Recruiting
Site Public Contact · Contact
Leopoldo J. Fernandez · Principal Investigator

Carilion Roanoke Memorial Hospital

Roanoke, Virginia, 24033

Suspended

Valley Health / Winchester Medical Center

Winchester, Virginia, 22601

Suspended

Fred Hutchinson Cancer Center

Seattle, Washington, 98109

Suspended

University of Washington Medical Center - Montlake

Seattle, Washington, 98195

Suspended

Duluth Clinic Ashland

Ashland, Wisconsin, 54806

Suspended

Northwest Wisconsin Cancer Center

Ashland, Wisconsin, 54806

Suspended

Essentia Health-Hayward Clinic

Hayward, Wisconsin, 54843

Suspended

Tamarack Health Hayward Medical Center

Hayward, Wisconsin, 54843

Suspended

Marshfield Medical Center-Marshfield

Marshfield, Wisconsin, 54449

Recruiting
Jessica A. Wernberg · Principal Investigator

ProHealth D N Greenwald Center

Mukwonago, Wisconsin, 53149

Suspended

ProHealth Oconomowoc Memorial Hospital

Oconomowoc, Wisconsin, 53066

Suspended

Essentia Health-Spooner Clinic

Spooner, Wisconsin, 54801

Suspended

Essentia Health Saint Mary's Hospital - Superior

Superior, Wisconsin, 54880

Suspended

ProHealth Waukesha Memorial Hospital

Waukesha, Wisconsin, 53188

Suspended

UW Cancer Center at ProHealth Care

Waukesha, Wisconsin, 53188

Suspended